Postoperative atrial-fibrillation (POAF) is common among surgical patients and associated with a worse outcome. Arterial-fibrillation (AF) is the most frequent complication arising after coronary-artery-bypass-grafting (CABG) surgery, occurring in 30% of cases. The incidence of this complication is even higher after valve-replacement surgery (30-40%) and after compound operative procedures (40-60%). Beta-blockers reduce POAF and supraventricular tachycardia and have direct antiarrhythmic activity. Landiolol hydrochloride, is an ultra-short-acting betablocker half-life of approximately 4 min. The selectivity ratio of landiolol is higher than other beta-blockers.
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PCV84 Methods
A decision-model was developed to reflect the cost-effectiveness of landiolol vs. no-prevention, standard-of-care (SoC) and esmolol for the patient group with different cardiac surgeries and a subgroup of CABG. The model benefit is expressed in a reduction in POAF episodes and reduced complications. Clinical data were derived mainly from the meta-analysis of Li et al. (2015) involving 807 patients (9 RCTs). Based on meta-analysis findings a decision tree model for two patient populations, (1) for patients with cardiac surgery in general and (2) for patients with CABG, was developed. The model calculates total inpatient costs (incl. surgery, ICU, complication and rehospitalisation) over the hospital-length-of-stay (LOS). Costs from published sources were used (2016 Euro) from the German hospital perspective. A one-way deterministic sensitivity-analysis accounts for uncertainty.
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Conclusion
The economic analysis of landiolol shows that the use is highly cost-effectiverepresent the lowest total cost in both patient populations and is associated with a superior effect to prevent POAF. Landiolol generates cost savings from the hospital perspective as well as the German health care system as whole.
Clinical Data
The economic model of landiolol was designed based on clinical trial data of the RCTs and the meta-analysis of Li et al. (2015) . In addition, a recent publication from Sezai and colleges (2015) was added.
The AF protecting effect of landiolol in the all-surgery patient population was: • The POAF incidence was 12.4% with landiolol and 36.7% for the control group.
• AF incidence for landiolol exhibits 13.5% compared to 38.4% for no prevention.
• AF incidence was 19.1% for landiolol and 39.2% for SOC.
The AF-protecting effect of landiolol in the CABG patient population is illustrated as follows:
• The POAF incidence was 12.1% with landiolol and 34.2% for the control group.
• AF incidence for landiolol exhibits 13.0% compared to 35.5% for no prevention.
• AF incidence was 8.8% for landiolol and 30.4% for SOC.
• For the indirect comparison the net effect of esmolol vs. control was calculated and expressed as adjusted trial difference of the SoC effect (30.4%) in the landiolol trial.
Resource Use and Costs
Resource use data were derived via literature search including German data to reflect the German clinical practice. The CEA collects hospitalization costs due to cardiac surgery (including ICU costs), costs of complication and hospital readmission. Medication costs for POAF prevention are covered in the German G-DRG lump sum. All costs were derived from public price lists, tariff catalogues and the literature. When necessary, prices were adjusted to 2016 prices using the consumer price index. Due to the short time horizon of the model, discounting of costs is not necessary.
Results
Patients with POAF had a higher incidence of mortality, morbidity and LOS including ICU and more frequent readmissions and finally higher costs. Per patient costs in the all-surgery population with landiolol are estimated between 24,234.21 €-25,910.02 € and AF occurred in 12. 4%-19 (1) perioperative landiolol vs (2) control (pooled control group, no prevention and SoC) (3) no prevention and (4) SoC, which is defined as other betablockers (oral) and diltiazem.
For the subgroup with CABG, esmolol is considered as an additional comparator. Landiolol and esmolol was not analysed within a clinical trial, therefore an indirect comparison was carried out. All patients are older than 65 years. 
Sensitivity Analysis
Deterministic sensitivity analysis (SA) was carried out. 
